<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40964167</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.</ArticleTitle><Pagination><StartPage>1627947</StartPage><MedlinePgn>1627947</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1627947</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1627947</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">To evaluate counterregulatory hormonal responses during a hypoglycemic clamp with tirzepatide.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Participants with type 2 diabetes (N=42) were randomized to tirzepatide (15 mg) or placebo for 12 weeks in a crossover design, with a wash-out period of 8-10 weeks. The primary objective was the change in glucagon response during clamp-induced hypoglycemia from plasma glucose (PG) 100 mg/dL to nadir PG (45 mg/dL). Secondary measures were changes in responses of other counterregulatory hormones during clamp-induced hypoglycemia. Time to recovery from the nadir to 72 mg/dL and hypoglycemic symptom scores using the 7-point Edinburgh Hypoglycemia Symptom scale were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At 12 weeks, HbA1c change from baseline was -1.5% with tirzepatide versus +0.5% with placebo. During induced hypoglycemia, mean PG levels at nadir were 44.5 mg/dL with tirzepatide and 47.5 mg/dL with placebo. Increases in glucagon from PG 100 mg/dL to nadir PG and during recovery from the nadir to 72 mg/dL did not differ between treatments (p=0.756 and p=0.565, respectively). Growth hormone and adrenaline responses did not differ between treatments. Cortisol and noradrenaline responses were delayed with tirzepatide, consistent with lower hypoglycemic symptom scores at nadir observed during tirzepatide treatment periods versus placebo (p=0.007). The proportion of participants aware of hypoglycemia did not differ between treatments.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The response of the key counterregulatory hormone glucagon to induced hypoglycemia was maintained with tirzepatide.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov, identifier NCT04050553.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Pieber, Svehlikova, Urva, Haupt, Zhou, Coskun, H&#xf6;ller, Fluhr, Karanikas, Milicevic and Pratt.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pieber</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz,&#xa0;Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svehlikova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz,&#xa0;Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urva</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN,&#xa0;United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN,&#xa0;United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chunmei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN,&#xa0;United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coskun</LastName><ForeName>Tamer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN,&#xa0;United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;ller</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz,&#xa0;Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fluhr</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz,&#xa0;Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karanikas</LastName><ForeName>Chrisanthi A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN,&#xa0;United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milicevic</LastName><ForeName>Zvonko</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Vienna,&#xa0;Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Edward John</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Lilly Centre for Clinical Pharmacology Pte Ltd, Singapore,&#xa0;Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04050553</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-92-5</RegistryNumber><NameOfSubstance UI="D005934">Glucagon</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>OYN3CCI6QE</RegistryNumber><NameOfSubstance UI="D000098860">Tirzepatide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015309" MajorTopicYN="N">Glucose Clamp Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="Y">Hypoglycemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000098860" MajorTopicYN="Y">Tirzepatide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">counterregulatory response</Keyword><Keyword MajorTopicYN="N">hypoglycemia</Keyword><Keyword MajorTopicYN="N">tirzepatide</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>TP reports grant support paid to theMedical University of Graz by Arecor, AstraZeneca, Novo Nordisk and Sanofi; personal compensation for consultation from Arecor, AstraZeneca, Eli Lilly and Company, Novo Nordisk and Sanofi. SU, AH, CZ, TC, CK, and EP are employees and shareholders of Eli Lilly and Company. ZM was an employee and shareholder of Eli Lilly and Company at the time of this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Eli Lilly and Company. The funder had the following involvement in the study: study design, collection, analysis, interpretation of data, the writing of this article and the decision to submit it for publication. The reviewer PF declared a past collaboration with one of the authors TP to the handling editor. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40964167</ArticleId><ArticleId IdType="pmc">PMC12436105</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1627947</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. (2010) 363:1410&#x2013;8. doi:&#xa0; 10.1056/NEJMoa1003795, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1003795</ArticleId><ArticleId IdType="pubmed">20925543</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. (2013) 347:f4533. doi:&#xa0; 10.1136/bmj.f4533, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f4533</ArticleId><ArticleId IdType="pubmed">23900314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. (2011) 124:993&#x2013;6. doi:&#xa0; 10.1016/j.amjmed.2011.08.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2011.08.008</ArticleId><ArticleId IdType="pmc">PMC3464092</ArticleId><ArticleId IdType="pubmed">22017775</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract. (2013) 19:792&#x2013;9. doi:&#xa0; 10.4158/EP12382.OR, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP12382.OR</ArticleId><ArticleId IdType="pubmed">23757608</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee . 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. (2025) 48:S181&#x2013;206. doi:&#xa0; 10.2337/dc25-S009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc25-S009</ArticleId><ArticleId IdType="pmc">PMC11635045</ArticleId><ArticleId IdType="pubmed">39651989</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. (2022) 45:2753&#x2013;86. doi:&#xa0; 10.2337/dci22-0034, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci22-0034</ArticleId><ArticleId IdType="pmc">PMC10008140</ArticleId><ArticleId IdType="pubmed">36148880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahr&#xe9;n B. GLP-1 for type 2 diabetes. Exp Cell Res. (2011) 317:1239&#x2013;45. doi:&#xa0; 10.1016/j.yexcr.2011.01.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2011.01.010</ArticleId><ArticleId IdType="pubmed">21237153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahr&#xe9;n B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. (1997) 82:473&#x2013;8. doi:&#xa0; 10.1210/jc.82.2.473</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.82.2.473</ArticleId><ArticleId IdType="pubmed">9024239</ArticleId></ArticleIdList></Reference><Reference><Citation>Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. (2004) 53:2397&#x2013;240. doi:&#xa0; 10.2337/diabetes.53.9.2397, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.9.2397</ArticleId><ArticleId IdType="pubmed">15331551</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsatko S, Jensen L, Brunner M, Sach-Friedl S, Tarp MD, Holst AG, et al. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. (2018) 20:2565&#x2013;73. doi:&#xa0; 10.1111/dom.13422, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13422</ArticleId><ArticleId IdType="pmc">PMC6221089</ArticleId><ArticleId IdType="pubmed">29893488</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. (2003) 46:798&#x2013;801. doi:&#xa0; 10.1007/s00125-003-1103-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-003-1103-y</ArticleId><ArticleId IdType="pubmed">12764578</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen M, Vedtofte L, Holst JJ, Vilsb&#xf8;ll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. (2011) 60:3103&#x2013;9. doi:&#xa0; 10.2337/db11-0979, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-0979</ArticleId><ArticleId IdType="pmc">PMC3219957</ArticleId><ArticleId IdType="pubmed">21984584</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen MB. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Dan Med J. (2016) 63:B5230.</Citation><ArticleIdList><ArticleId IdType="pubmed">27034187</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen MB, Calanna S, Holst JJ, Vilsb&#xf8;ll T, Knop FK. Glucose-dependent insulinotropic polypeptide: Blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab. (2014) 99:E418&#x2013;26. doi:&#xa0; 10.1210/jc.2013-3644, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2013-3644</ArticleId><ArticleId IdType="pubmed">24423311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Wysham C, Fr&#xed;as JP, Kaneko S, Lee CJ, Fern&#xe1;ndez Land&#xf3; L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. (2021) 398:143&#x2013;55. doi:&#xa0; 10.1016/S0140-6736(21)01324-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01324-6</ArticleId><ArticleId IdType="pubmed">34186022</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xed;as JP, Davies MJ, Rosenstock J, P&#xe9;rez Manghi FC, Fern&#xe1;ndez Land&#xf3; L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. (2021) 385:503&#x2013;15. doi:&#xa0; 10.1056/NEJMoa2107519, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107519</ArticleId><ArticleId IdType="pubmed">34170647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvik B, Giorgino F, J&#xf3;dar E, Frias JP, Fern&#xe1;ndez Land&#xf3; L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. (2021) 398:583&#x2013;98. doi:&#xa0; 10.1016/S0140-6736(21)01443-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01443-4</ArticleId><ArticleId IdType="pubmed">34370970</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. (2021) 398:1811&#x2013;24. doi:&#xa0; 10.1016/S0140-6736(21)02188-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02188-7</ArticleId><ArticleId IdType="pubmed">34672967</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl D, Onishi Y, Norwood P, Huh R, Patel H, Rodr&#xed;guez A. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. (2022) 327:534&#x2013;45. doi:&#xa0; 10.1001/jama.2022.0078, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0078</ArticleId><ArticleId IdType="pmc">PMC8826179</ArticleId><ArticleId IdType="pubmed">35133415</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. (2018) 18:3&#x2013;14. doi:&#xa0; 10.1016/j.molmet.2018.09.009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2018.09.009</ArticleId><ArticleId IdType="pmc">PMC6308032</ArticleId><ArticleId IdType="pubmed">30473097</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Hepburn DA, MacLeod KM. Frier BM. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia. (1993) 36:771&#x2013;7. doi:&#xa0; 10.1007/BF00401150, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00401150</ArticleId><ArticleId IdType="pubmed">8405746</ArticleId></ArticleIdList></Reference><Reference><Citation>Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. (2008) 358:2545&#x2013;59. doi:&#xa0; 10.1056/NEJMoa0802743, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802743</ArticleId><ArticleId IdType="pmc">PMC4551392</ArticleId><ArticleId IdType="pubmed">18539917</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, et al. Counter-regulatory hormone responses to hypoglycaemia in subjects with type 1 diabetes following 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. (2015) 17:742&#x2013;50. doi:&#xa0; 10.1111/dom.12473, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12473</ArticleId><ArticleId IdType="pubmed">25855340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck MA, El Ouaghlidi A, Hompesch M, Jacobsen J, Elbroend B. No impairment of hypoglycemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with type 2-diabetes. Diabetologia. (2003) 46:A285.</Citation></Reference><Reference><Citation>Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y, et al. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes Metab. (2017) 19:442&#x2013;7. doi:&#xa0; 10.1111/dom.12817, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12817</ArticleId><ArticleId IdType="pmc">PMC5347937</ArticleId><ArticleId IdType="pubmed">27800649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hompesch M, Jones-Leone A, Carr MC, Matthews J, Zhi H, Young M, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. (2015) 17:82&#x2013;90. doi:&#xa0; 10.1111/dom.12398, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12398</ArticleId><ArticleId IdType="pubmed">25263215</ArticleId></ArticleIdList></Reference><Reference><Citation>Farngren J, Persson M, Ahren B. Effect of the GLP-1 receptor agonist lixisenatide on counterregulatory responses to hypoglyemia in subjects with insulin-treated type 2 diabetes. Diabetes Care. (2016) 39:242&#x2013;9. doi:&#xa0; 10.2337/dc15-1274, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-1274</ArticleId><ArticleId IdType="pubmed">26537183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. (2002) 87:1239&#x2013;46. doi:&#xa0; 10.1210/jcem.87.3.8355, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.3.8355</ArticleId><ArticleId IdType="pubmed">11889194</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabricius TW, Verhulst CEM, Kristensen PL, Tack CJ, McCrimmon RJ, Heller S, et al. Hyperinsulinaemic-hypoglycaemic glucose clamps in human research: a systematic review of the literature. Diabetologia. (2021) 64:727&#x2013;36. doi:&#xa0; 10.1007/s00125-020-05361-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-020-05361-8</ArticleId><ArticleId IdType="pmc">PMC7940281</ArticleId><ArticleId IdType="pubmed">33566134</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen M, Bagger JI, Vilsb&#xf8;ll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. Rev Diabetes Stud. (2011) 8:369&#x2013;81. doi:&#xa0; 10.1900/RDS.2011.8.369, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1900/RDS.2011.8.369</ArticleId><ArticleId IdType="pmc">PMC3280671</ArticleId><ArticleId IdType="pubmed">22262074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund A, Bagger JI, Christensen M, Knop FK, Vilsb&#xf8;ll T. Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diabetes Rep. (2014) 14:555. doi:&#xa0; 10.1007/s11892-014-0555-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-014-0555-4</ArticleId><ArticleId IdType="pubmed">25344790</ArticleId></ArticleIdList></Reference><Reference><Citation>De Feo P, Perriello G, Torlone E, Ventura MM, Fanelli C, Santeusanio F, et al. Contribution of cortisol to glucose counterregulation in humans. Am J Physiol. (1989) 257:E35&#x2013;42. doi:&#xa0; 10.1152/ajpendo.1989.257.1.E35, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.1989.257.1.E35</ArticleId><ArticleId IdType="pubmed">2665516</ArticleId></ArticleIdList></Reference><Reference><Citation>De Feo P, Perriello G, Torlone E, Ventura MM, Fanelli C, Santeusanio F, et al. Demonstration of a role for growth hormone in glucose counterregulation. Am J Physiol. (1989) 256:E835&#x2013;43. doi:&#xa0; 10.1152/ajpendo.1989.256.6.E835, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.1989.256.6.E835</ArticleId><ArticleId IdType="pubmed">2567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PJ, Cryer PE. Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol. (1991) 260:E395&#x2013;402. doi:&#xa0; 10.1152/ajpendo.1991.260.3.E395, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.1991.260.3.E395</ArticleId><ArticleId IdType="pubmed">2003593</ArticleId></ArticleIdList></Reference><Reference><Citation>Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. (2022) 10:418&#x2013;29. doi:&#xa0; 10.1016/S2213-8587(22)00085-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00085-7</ArticleId><ArticleId IdType="pubmed">35468322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. (2005) 28:2948&#x2013;61. doi:&#xa0; 10.2337/diacare.28.12.2948, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.28.12.2948</ArticleId><ArticleId IdType="pubmed">16306561</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>